secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001649094-25-000112
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025
--------------------------------------------------------------------------------

- Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.
- Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.
- Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.
- VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.
- Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/0001649094-25-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001649094-25-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer